Ramon A Franco1, Inna Husain2, Lindsay Reder3, Paul Paddle4. 1. Division of Laryngology, Department of Otolaryngology, Harvard Medical School and Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, U.S.A. 2. Department of Otolaryngology, Rush University Medical Center, Chicago, Illinois, U.S.A. 3. Department of Otolaryngology, University of Southern California, Los Angeles, California, U.S.A. 4. Monash Health and Alfred Health, Victoria, Melbourne, Australia.
Abstract
OBJECTIVES/HYPOTHESIS: The fibrotic/erythematous appearance of the subglottis in idiopathic subglottic stenosis (iSGS) hints that it might respond to repeated intralesional steroid treatment similar to keloids. STUDY DESIGN: Retrospective cohort study. METHODS: Thirteen iSGS subjects (six treated in-office with serial intralesional steroid injections [SILSI] versus seven treated endoscopically in the operating room [OR] followed by awake SILSI) between October 2011 and April 2017. Forced spirometry was performed before injections and at each follow-up visit (peak expiratory flow [%PEF] and peak inspiratory flow). Steroids were injected via transcricothyroid or transnasal routes. Injections were grouped into rounds of four to six injections separated by 3 to 5 weeks. RESULTS: Thirteen subjects with a mean follow-up of 3 years (3.3 years for SILSI and 2.7 years for OR). Awake-only SILSI subjects had a mean improvement/round of 23.1% %PEF (range, 65.4%-88.6%), whereas the OR-treated subjects had a mean %PEF improvement/round of 25.1% (range, 57.4%-82.5%). Both groups had improved breathing, and the improvements were statistically equal (P = .569). SILSI subjects underwent 5.3 injections/round in 1.3 rounds, whereas OR subjects had 5.9 injections/round over 2.1 rounds. Statistically significant improvement was seen in %PEF for both groups (SILSI P = .007, OR P = .002). Overall, SILSI achieved sustained %PEF above 80% in 83% (5/6) and OR + SILSI 86% (6/7). CONCLUSIONS: SILSI in the awake outpatient setting can improve the airway caliber in iSGS and is equivalent to endoscopic OR treatment. We believe iSGS can be viewed as a chronic scarring/inflammatory condition that can benefit from steroid scar-modification therapy. LEVEL OF EVIDENCE: 4. Laryngoscope, 128:610-617, 2018.
OBJECTIVES/HYPOTHESIS: The fibrotic/erythematous appearance of the subglottis in idiopathic subglottic stenosis (iSGS) hints that it might respond to repeated intralesional steroid treatment similar to keloids. STUDY DESIGN: Retrospective cohort study. METHODS: Thirteen iSGS subjects (six treated in-office with serial intralesional steroid injections [SILSI] versus seven treated endoscopically in the operating room [OR] followed by awake SILSI) between October 2011 and April 2017. Forced spirometry was performed before injections and at each follow-up visit (peak expiratory flow [%PEF] and peak inspiratory flow). Steroids were injected via transcricothyroid or transnasal routes. Injections were grouped into rounds of four to six injections separated by 3 to 5 weeks. RESULTS: Thirteen subjects with a mean follow-up of 3 years (3.3 years for SILSI and 2.7 years for OR). Awake-only SILSI subjects had a mean improvement/round of 23.1% %PEF (range, 65.4%-88.6%), whereas the OR-treated subjects had a mean %PEF improvement/round of 25.1% (range, 57.4%-82.5%). Both groups had improved breathing, and the improvements were statistically equal (P = .569). SILSI subjects underwent 5.3 injections/round in 1.3 rounds, whereas OR subjects had 5.9 injections/round over 2.1 rounds. Statistically significant improvement was seen in %PEF for both groups (SILSI P = .007, OR P = .002). Overall, SILSI achieved sustained %PEF above 80% in 83% (5/6) and OR + SILSI 86% (6/7). CONCLUSIONS: SILSI in the awake outpatient setting can improve the airway caliber in iSGS and is equivalent to endoscopic OR treatment. We believe iSGS can be viewed as a chronic scarring/inflammatory condition that can benefit from steroid scar-modification therapy. LEVEL OF EVIDENCE: 4. Laryngoscope, 128:610-617, 2018.
Authors: Jost Kaufmann; Katrin Bode; Christian Puder; Michael Laschat; Thomas Engelhardt; Frank Wappler Journal: Eur Arch Otorhinolaryngol Date: 2019-09-17 Impact factor: 2.503
Authors: Robert J Morrison; Nicolas-George Katsantonis; Kevin M Motz; Alexander T Hillel; C Gaelyn Garrett; James L Netterville; Christopher T Wootten; Susan M Majka; Timothy S Blackwell; Wonder P Drake; Alexander Gelbard Journal: Otolaryngol Head Neck Surg Date: 2018-10-16 Impact factor: 3.497
Authors: Caitlin Bertelsen; Hagit Shoffel-Havakuk; Karla O'Dell; Michael M Johns; Lindsay S Reder Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-03-01 Impact factor: 6.223
Authors: Stephen S Schoeff; Xudong Shi; William G Young; Chad W Whited; Resha S Soni; Peng Liu; Irene M Ong; Seth H Dailey; Nathan V Welham Journal: Laryngoscope Date: 2020-07-03 Impact factor: 3.325
Authors: Melissa M Liu; Kevin M Motz; Michael K Murphy; Linda X Yin; Dacheng Ding; Alexander Gelbard; Alexander T Hillel Journal: Laryngoscope Date: 2020-05-05 Impact factor: 2.970
Authors: Marta Filauro; Francesco Mazzola; Francesco Missale; Frank Rikki Canevari; Giorgio Peretti Journal: Front Pediatr Date: 2020-01-08 Impact factor: 3.418